A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The possibility of eradicating cancer by selective destruction of tumour blood vessels may represent an attractive therapeutic avenue, but most pharmaceutical agents investigated so far did not achieve complete cures and are not completely specific. Antibody conjugates now allow us to evaluate the impact of selective vascular shutdown on tumour viability and to study mechanisms of action. METHODS: We synthesised a novel porphyrin-based photosensitiser suitable for conjugation to antibodies and assessed anticancer properties of its conjugate with L19, a clinical-stage human monoclonal antibody specific to the alternatively spliced EDB domain of fibronectin, a marker of tumour angiogenesis. RESULTS: Here we show in two mouse model of cancer (F9 and A431) that L19 is capable of highly selective in vivo localisation around tumour blood vessels and that its conjugate with a photosensitiser allows selective disruption of tumour vasculature upon irradiation, leading to complete and long-lasting cancer eradication. Furthermore, depletion experiments revealed that natural killer cells are essential for the induction of long-lasting complete responses. CONCLUSIONS: These results reinforce the concept that vascular shutdown can induce a curative avalanche of tumour cell death. Immuno-photodynamic therapy may be particularly indicated for squamous cell carcinoma of the skin, which we show to be strongly positive for markers of angiogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“Inhibition of key mediators of tumour angiogenesis has culminated in the clinical application of Avastin, a humanised monoclonal antibody binding soluble VEGF-A, thus stopping interaction with its receptors (Ferrara et al, 2004; Hurwitz et al, 2004).”
BackgroundFolkman, J. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131306 · Cited by 1,209
Umaña, P., Jean–Mairet, J., Moudry, R., Amstutz, H., & Bailey, J. E. (1999) · Nature Biotechnology · doi:10.1038/6179 · Cited by 764 · cited 1×
“Furthermore, protein engineering strategies that increase the binding affinity of antibodies to the cognate Fc receptor may dramatically potentiate the anticancer activity of therapeutic antibodies (Umana et al, 1999; Presta et al, 2002; Nimmerjahn and Ravetch, 2005).”
Background
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Josefsen, L. B., & Boyle, R. W. (2012) · Theranostics · doi:10.7150/thno.4571 · Cited by 575
Self-citationAntibody-drug conjugates—an emerging class of cancer treatment
Diamantis, N., & Banerji, U. (2016) · British Journal of Cancer · doi:10.1038/bjc.2015.435 · Cited by 525
Antibody–drug conjugates: current status and future directions
Perez, H. L., Cardarelli, P. M., Deshpande, S., Gangwar, S., Schroeder, G. M., Vite, G. D., & Borzilleri, R. M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.004 · Cited by 470
The state-of-play and future of antibody therapeutics
Elgundi, Z., Reslan, M., Cruz, E., Sifniotis, V., & Kayser, V. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.11.004 · Cited by 322
Curative Properties of Noninternalizing Antibody–Drug Conjugates Based on Maytansinoids
Perrino, E., Steiner, M., Krall, N., Bernardes, G. J. L., Pretto, F., Casi, G., & Neri, D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2990 · Cited by 130
Self-citationTumor rim cells: From resistance to vascular targeting agents to complete tumor ablation
Seidi, K., Jahanban-Esfahlan, R., & Zarghami, N. (2017) · Tumor Biology · doi:10.1177/1010428317691001 · Cited by 41
Metadata
- Authors
- Palumbo, A., Hauler, F., Dziunycz, P., Schwager, K., Soltermann, A., Pretto, F., Alonso, C., Hofbauer, G. F., Boyle, R. W., & Neri, D.
- Venue
- British Journal of Cancer
- Published
- 2011-03
- Volume
- 104
- Issue
- 7
- Pages
- 1106-1115
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2106444953
- Cited by
- 70
- References
- 3
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.